Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Halberd Corp (OP: HALB )

0.0037 UNCHANGED
Streaming Delayed Price Updated: 3:32 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halberd Corp

< Previous 1 2 3 4 5 Next >
"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!
Via ACCESSWIRE
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Via ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Via ACCESSWIRE
Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer
Via ACCESSWIRE
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Via ACCESSWIRE
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
Via ACCESSWIRE
Halberd Laser Therapy Eliminates over 90% of Multiple Antibiotic Resistant Bacteria in Minutes
Via ACCESSWIRE
Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
Via ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
Via ACCESSWIRE
Halberd Enters Strategic Alliance for Longevity, Alzheimer's Disease, and Cancer Early Detection, Prevention and Treatment
Jackson Center, Pennsylvania--(Newsfile Corp. - September 27, 2022) - Halberd Corporation (OTC Pink: HALB) entered into a strategic alliance with AI... 
Via Newsfile
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence
Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein
Via ACCESSWIRE
NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
Via ACCESSWIRE
Halberd Corporation Discusses OTCQB Uplisting and Growing List of Proprietary Technologies with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - July 28, 2022) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB), a publicly... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
Via ACCESSWIRE
Halberd Corp. Launches "Halberd Cancer Therapeutics, LTD" Wholly Owned Subsidiary
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Halberd's Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron
Boosts Effectiveness of Commercial Covid Antibodies by 45% 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Halberd Corporation Update, CEO Letter and 2022 Expectations
Q2 Accomplishments and a Look to the Future 
From Halberd Corporation
Via AccessWire
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of... 
From Halberd Corporation
Via AccessWire
Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the... 
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Exposures Animal Testing Product Safety
Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
JACKSON CENTER, PA / ACCESSWIRE / May 24, 2022 / Halberd Corporation (OTC PINK:HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted... 
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Exposures Animal Testing Product Safety
Halberd Engages Professional Firm to Proceed with FDA Filings
JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug... 
From Halberd Corporation
Via AccessWire
Exposures Product Safety
Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
JACKSON CENTER, PA / ACCESSWIRE / May 12, 2022 / Halberd Corporation (OTC PINK:HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step... 
From Halberd Corporation
Via AccessWire
Topics Animal Testing Regulatory Compliance
Exposures Animal Testing Legal Product Safety
Dr. Gregg Sturrus' TEDx Talk(R) Features Halberd's Extracorporeal Treatment of Neurodegenerative Diseases
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Halberd Corporation
Via AccessWire
Halberd CEO Letter
Q1 Accomplishments and Q2 Plans JACKSON CENTER, PA / ACCESSWIRE / April 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter has witnessed some very... 
From Halberd Corporation
Via AccessWire
Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics
JACKSON CENTER, PA / ACCESSWIRE / April 18, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease... 
From Halberd Corporation
Via AccessWire
Topics Animal Testing
Exposures Animal Testing
Halberd Entering the Medical Metaverse(TM)
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2022 / Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to... 
From Halberd Corporation
Via AccessWire
Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation (OTC PINK:HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target... 
From Halberd Corporation
Via AccessWire
Halberd Expands Its Technical Expertise with the Addition of Microbiology Professor
JACKSON CENTER, PA / ACCESSWIRE / March 8, 2022 / Halberd Corporation (OTC PINK:HALB) is pleased to announce Youngstown State University's (YSU) Dr. Chester R. Cooper has joined its technical team. Dr.... 
From Halberd Corporation
Via AccessWire
Halberd's COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
Outperforms Approved COVID Antibodies JACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporation's (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding... 
From Halberd Corporation
Via AccessWire
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.